Panstay-DSR

Domperidone may reduce Hypoprolactinaemic effect of Bromocriptine. Intake of pantoprazole is not associated with impaired response to clopidogrel as is the case with Omeprazole.

1) Very rarely extrapyramidal syndrome - e.g. Parkinsonism, tardive dyskinesia. 2) Domperidone may cause galactorrhoea and gynaecomastia due to                                     Hyperprolactinaemia 3) Other minor side effects Dry mouth, thirst Headache Nervousness Diarrhea Skin rash, itching Increase in TSH level, hypothyroid woman.

Patients with known allergies to Domperidone. Pregnancy Use with caution in children except in cancer chemotherapy.

Panstay-DSR owing to its Sustained release effect offers convenient once a day dose. It is to be taken orally with a sip of water early morning with an empty stomach at least half hour before eating anything. The dose may be increased to twice a day: one in morning empty stomach and one in evening at least half an hour before dinner. This is necessary only in conditions with uncontrolled acidity and vomiting as soon as the patient consumes anything.

Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Maintenance of Healing of Erosive Esophagitis Pathological Hypersecretory Conditions Including Zollinger- Ellison Syndrome (ZES). Duodenal ulcers Gastric ulcers NSAIDs induced ulcers Gastroperesis Functional dyspepsia NSAID induced ulcers

Powerful synergistic combination for faster healing GERD and erosive esophagitis. Rapid and lasting reduction in acid production. Increases lower esophageal tone and esophageal clearance. Round the clock relief from GERD in lower dose due to sustained release dosage form. Convenience once daily dose increases compliance. More effective in 24-hour intragastric pH profiles than Omeprazole. Low potential to interact with the cytochrome P450 enzyme system. Steady state serum concentration.